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ABSTRACT
Objectives: To evaluate clinicopathological and perioperative factors associated with the risk
of focal and non-focal positive surgical margins (PSMs) after robot-assisted radical prosta-
tectomy (RARP).
Patients and methods: The study was retrospective and excluded patients who were under
androgen-deprivation therapy or had prior treatments. The population included: negative SM
cases (control group), focal and non-focal PSM cases (study groups). PSMs were classiﬁed as
focal when the linear extent of cancer invasion was ≤1 mm and non-focal when >1 mm. The
independent association of factors with the risk of focal and non-focal PSMs was assessed by
multinomial logistic regression.
Results: In all, 732 patients underwent RARP, from January 2013 to December 2017. An
extended pelvic lymph node dissection was performed in 342 cases (46.7%). In all, 192 cases
(26.3%) had PSMs, which were focal in 133 (18.2%) and non-focal in 59 (8.1%). Independent
factors associated with the risk of focal PSMs were body mass index (odds ratio [OR] 0.914;
P = 0.006), percentage of biopsy positive cores (BPC; OR 1.011; P = 0.015), pathological
extracapsular extension (pathological tumour stage [pT]3a; OR 2.064; P = 0.016), and seminal
vesicle invasion (pT3b; OR 2.150; P = 0.010). High surgeon volume was a protective factor in
having focal PSM (OR 0.574; P = 0.006). Independent predictors of non-focal PSMs were BPC
(OR 1,013; P = 0,044), pT3a (OR 4,832; P < 0.001), and pT3b (OR 5,153; P = 0.001).
Conclusions: In high-volume centres features related to host, tumour and surgeon volume
are factors that predict the risk of focal and non-focal PSMs after RARP.
Abbreviations: AJCC: American joint committee on cancer; AS: active surveillance; ASA:
American society of anesthesiologists; BCR: biochemical recurrence; BMI: body mass index;
BPC: percentage of biopsy positive cores; ePLND: extended lymph node dissection; H&E:
haematoxylin and eosin; IQR, interquartile range; ISUP: international society of urologic
pathology; LNI: lymph node invasion; LOS: length of hospital stay; mpMRI: multiparametric
MRI; (c)(p)N: (clinical) (pathological) nodal stage; OR: odds ratio; OT: operating time; PSA-DT:
PSA-doubling time; (P)SM: (positive) surgical margin; (NS)(RA)RP: (nerve-sparing) (robot-assisted)
radical prostatectomy; RT: radiation therapy; (c)(p)T: (clinical) (pathological) tumour stage
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Introduction
Prostate cancer is the most common non-cutaneous
malignancy and the second leading cause of cancer-
related deaths in men [1]. The disease requires
a clinical risk evaluation [2] in order to plan suitable
management options, which include: active surveil-
lance (AS), radical prostatectomy (RP), and radiation
therapy (RT) [3]. Today, RP is performed more fre-
quently using the robot-assisted RP (RARP) approach.
An unfavourable outcome after RP is the detection of
positive surgical margins (PSMs), which expose
patients to the risk of a second treatment including
adjuvant or salvage RT, with or without androgen
blockade because of disease recurrence [3–10]. High-
grade tumours extending beyond the prostate with
a PSM and PSA-doubling time (PSA-DT) of <3 months
represent negative prognostic factors for metastases
and prostate cancer-speciﬁc mortality [4,11,12].
Patients who have extraprostatic disease with PSMs
need appropriate counselling for further management
options that include: immediate RT (after recovery of
the urinary function) or close PSA monitoring with
salvage RT before the PSA level approaches values
>0.1 ng/mL [3]. These issues impair the quality of life
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of the aﬀected patients, due not only to anxiety but
also the toxicities related to treatments [3].
The unfavourable outcome of detecting PSMs after
RP depends on both tumour biology and surgeon
experience [3–10]. In high-volume centres, experi-
enced surgeons can achieve comparable PSM rates
[13]. In contemporary patient cohorts undergoing
RARP, it is important to assess factors associated
with the risk of PSM by the linear extent, which has
prognostic value for disease recurrence [3–10]. The
aim of the present study was to evaluate clinicopatho-
logical and perioperative factors associated with the
risk of focal and non-focal PSMs in a contemporary
cohort of patients undergoing RARP in a high-volume
centre.
Patients and methods
Study features
The study was retrospective, had Institutional Review
Board approval, and included the period from
January 2013 to December 2017. Each patient pro-
vided informed-signed consent for use of data. All
patients who were under androgen blockade and/or
had prior treatments were excluded.
Clinical features
Preoperative patient data included age and body mass
index (BMI; kg/m2). The serum levels of PSA (ng/mL)
were determined by radioimmunoassay. Prostate biop-
sies had the following features: (i) at least 12–14 cores;
(ii) number of positive cores; (iii) measurement of pros-
tate volume (mL); (iv) tumour classiﬁed by biopsy
grade groups according to the 2014 International
Society of Urologic Pathology (ISUP) system [14,15]. In
each patient, the number of positive cores over the
total number of cores taken (percentage of biopsy
positive cores [BPC]) was evaluated. Patients were clini-
cally staged for the tumour (cT) and nodal (cN) status
using the 2010 American Joint Committee on Cancer
(AJCC) staging system for prostate cancer (7th edition)
[16]. Tumours were staged by DRE and/or by multi-
parametric MRI (mpMRI). Pelvic lymph nodes were
assessed by CT or mpMRI. Enlarged pelvic nodes mea-
suring >1 cm in diameter along its longest axis were
staged as cN1. The metastatic status was assessed by
CT and/or mpMRI, as well as by skeletal scintigraphy.
Patients were then classiﬁed according to D’Amico risk
classes [2].
Extended lymph node dissection (ePLND) was per-
formed when the risk of lymph node invasion (LNI)
was >5% [17]. In low-risk patients, the decision to
perform an ePLND was based on clinical factors indi-
cating increased risk of tumour upgrading in the sur-
gical specimen [18–23].
Perioperative features
RARP was performed using the da Vinci® Robot System
(Intuitive Surgical Inc., Sunnyvale, CA, USA) via
a transperitoneal approach, with antegrade prostatic
dissection [24]. Nerve-sparing RP (NSRP) was underta-
ken when indicated [25]. According to the nerve-
sparing status, the prostate was dissected by an intra-
fascial, interfascial or extrafascial technique [26]. RARP
was performed by ﬁve experienced surgeons using
a bladder neck-sparing technique [27]. All of these
surgeons completed the RARP learning curve before
the beginning of the present patients’ enrolment. The
single high-volume surgeon had already performed
>500 RARPs when patient enrolment started. The
other four surgeons (low-volume surgeons) had
already performed between 50 and 60 procedures at
the commencement of patient enrolment.
The high-volume surgeon (W.A.) performed two-
thirds of the procedures. Intraoperatively, operating
time (OT, min) and blood loss (mL) were measured.
Preoperatively, patients’ surgical risk was evaluated
using the American Anesthesiologists Score (ASA) sys-
tem [28]. Postoperatively, the length of hospital stay
(LOS) was recorded in each patient who was assessed
and followed for a period of 6 months, to detect
hospital readmission and complications, which were
classiﬁed according to the Clavien–Dindo system [29].
Pathological features
Specimens were processed according to the Stanford
protocol by dedicated pathologists [20]. Prostate weight
(g) was calculated and tumours were classiﬁed accord-
ing to the ISUP pathological grade group system [14,15].
Nodal packets were grouped according to a standard
template and submitted in separate packages. Lymph
nodes were histopathologically assessed after haema-
toxylin and eosin (H&E) staining. Immunohistochemical
staining was performed if appropriate. In every case, the
numbers of removed and metastatic nodes were eval-
uated. Specimens were staged using the 2010 AJCC
staging system for prostate cancer (pathological tumour
stage [pT] and pathology nodal stage [pN] status).
SMs were considered positive when cancer
invaded the inked surface of the specimen. When
the linear extension of cancer involvement on the
inked surface was ≤1 mm the PSM was classiﬁed as
focal, otherwise it was coded as non-focal (Figure 1).
According to the anatomical location, PSMs were clas-
siﬁed as apical, posterolateral (left and right), poster-
ior, anterior, and bladder neck.
Study design
The patient population was divided into three groups
including: negative SM cases (no PSM; control group),
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as well as focal and non-focal PSM patients (study
groups). The associations of focal and non-focal
PSMs with clinicopathological and perioperative fac-
tors were evaluated. Clinical variables assessed
included: age, BMI, PSA level, prostate volume, BPC,
biopsy grade group, cT stage, cN stage, and D’Amico’s
class risk. The pathological factors assessed included:
prostate weight, pathological grade group, pT, and
pN. Perioperative factors assessed included: OT,
blood loss, ePLND, number of dissected nodes,
NSRP, surgeon volume, ASA score, LOS, Clavien–
Dindo score, and readmission.
Statistical analysis
Summary statistics and distributions of factors
amongst the three groups (negative SM, focal PSM,
and non-focal PSM) were assessed. Data on continu-
ous variables were reported as medians with their
respective interquartile ranges (IQRs). Data on catego-
rical variables were presented as frequencies with
relative percentages. Associations of factors amongst
the three groups were analysed by the Kruskal–Wallis
test for continuous variables, and by the Pearson’s
chi-squared test or Fisher’s exact test, as appropriate
for categorical ones. Signiﬁcant factors were entered
into the multivariate model. The multinomial logistic
regression model (multivariate analysis) evaluated the
associations between factors and the risk of focal and
non-focal PSMs when compared to negative SM cases
(control group). Clinical, pathological and periopera-
tive factors were evaluated separately. An overall mul-
tivariate model including independent factors of each
set (clinical, pathological and perioperative) was also
computed.
The software used for the analysis was the IBM
Statistical Package for the Social Sciences (SPSS®),
version 20 (SPSS Inc., IBM Corp., Armonk, NY, USA).
All tests were two-sided with P < 0.05 considered to
indicate statistical signiﬁcance.
Results
We evaluated 732 patients who underwent RARP
(Table 1). The median age of the patients was
65 years and the median PSA level was 6.3 ng/mL.
The intermediate-risk class included 50.1% of the
patients. The remaining population encompassed
low-risk (34.2%) and high-risk patients (15.7%).
Extraprostatic extension was present in 21.9% of
patients and showed high-grade cancer (pathological
grade group 4–5) in 19.5% of patients. Amongst the
342 patients who had an ePLND, LNI was detected in
49 (14.3%). The median number of dissected nodes
was 26. In patients with LNI, the median (IQR) number
of positive nodes was 1 (1–3). The high-volume sur-
geon performed 66.1% of the procedures. NSRP was
performed in 82% of the patients. Major complica-
tions (Clavien–Dindo score >2) were detected in
2.9% of the patients.
Overall (Table 1), 192 patients had PSMs (26.3%),
which were classiﬁed as focal in 133 (18.2%) and non-
focal in 59 (8.1%). Figure 2 shows the frequency of PSM
sites stratiﬁed by linear extension amongst these
patients. The predictors of PSMs and negative SMs in
this cohort has been previously presented [30].
Considering clinical factors, signiﬁcant associations of
BMI, PSA level, BPC and biopsy grade group with focal
and non-focal PSMs were detected. Amongst groups,
the association was negative for BMI and positive for
other factors. Amongst pathological factors, signiﬁcant
positive associations of extraprostatic disease, high-
grade tumours and LNI with focal and non-focal PSMs
were assessed. The presence of extraprostatic disease,
high-grade tumours and LNI were positively associated
with the risk of focal and non-focal PSMs (Table 1).
Considering perioperative factors, performing ePLND
was positively associated with the risk focal and non-
focal PSMs, high surgeon volume was negatively asso-
ciated with focal and non-focal PSMs.
We evaluated diﬀerent multivariate models includ-
ing clinical, pathological and perioperative factors
Figure 1. Histopathological images of focal and non-focal PSMs. The arrows indicate the PSM site. (A) The inked margin has
neoplastic cells with a length ≤1 mm, i.e. focal PSM (H&E, ×10). (B) The inked margin has neoplastic cells with a length >1 mm,
i.e. non-focal (in the present case, the entire inked margin is involved. H&E, ×10).
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(Table 2); moreover, combined models were also
assessed (Table 2). Considering each model, the risk
of focal PSM was predicted by BMI (odds ratio [OR]
0.919; P = 0.009) and BPC (OR 1.013; P = 0.005) in the
clinical model, by extracapsular extension (OR 1.972;
P = 0.027) in the pathological model; by ePLND (OR
1.675; P = 0.009) and high surgeon volume (OR 0.609;
P = 0.013) in the perioperative model (Table 2).
Moreover, in the clinical and perioperative models,
focal PSMs were predicted by BMI (OR 0.915;
P = 0.006), BPC (OR 1.012; P = 0.014) and high surgeon
volume (OR 0.577; P = 0.007). In the overall model,
BMI (OR 0.914; P = 0.006), BPC (OR 1.011; P = 0.015),
pT3a (OR 2.064; P = 0.016), pT3b (OR 2.150; P = 0.010)
and high surgeon volume (OR 0.574; P = 0.006) were
associated with the risk of focal PSMs (Table 3).
Table 1. Associations of factors with PSM in the 732 patients who underwent RARP.
SMs
Variable Population Negative Focal PSM Non-focal PSM P
Number of patients, (%) 732 540 (73.8) 133 (18.2) 59 (8.1)
Clinical factors
Age, years, median (IQR) 65 (60–69) 65 (60–69) 65 (61–70) 62 (57–68) 0.089
BMI, kg/m2, median (IQR) 25.8 (23.8–28) 26 (24–28) 25.1 (23.3–27.2) 25.3 (23.4–28.4) 0.035
PSA, ng/mL, median (IQR) 6.3 (4.9–8.7) 6.1 (4.8–8.3) 6.9 (5.1–8.9) 6.9 (5.1–11.3) 0.007
Prostate volume, mL, median (IQR) 39 (30–50) 40 (30–50) 39 (30–48.8) 35 (27–45) 0.202
BPC, %, median (IQR) 29 (17–45.7) 28 (17–42) 33 (21–50) 35 (21–57) <0.001
Clinical T stage, n (%)
cT1c 517 (70.6) 390 (72.2) 83 (62.4) 44 (74.6) 0.232
cT2 194 (26.5) 135 (25) 45 (33.8) 14 (23.7)
cT3 21 (2.9) 15 (2.8) 24 (18) 1 (1.7)
Clinical N stage, n (%)
cN0 710 (97) 522 (96.7) 130 (97.7) 58 (98.3) 0.669
cN1 22 (3) 18 (3.3) 3 (2.3) 1 (1.7)
Biopsy grade group, n (%)
1 343 (46,9) 262 (48.5) 54 (40.6) 27 (45.8) 0.030
2–3 315 (43) 229 (42.4) 66 (49.6) 20 (33.9)
4–5 74 (10.1) 49 (9.1) 13 (9.8) 12 (20.3)
Risk class, n (%)
Low 250 (34.2) 193 (35.7) 37 (27.8) 20 (33.9) 0.079
Intermediate 367 (50.1) 271 (50.2) 72 (54.1) 24 (40.7)
High 115 (15.7) 76 (14.1) 24 (18) 15 (13)
Pathological factors
Prostate weight, g, median (IQR) 50 (41–63) 52 (44–63.6) 51 (40.2–63.7) 50 (41.2–28.5) 0.226
Pathological grade group, n (%)
1 126 (17.2) 107 (19.8) 15 (11.3) 4 (6.8) <0.001
2–3 463 (63.3) 350 (64.8) 82 (61.7) 31 (52.5)
4–5 143 (19.5) 83 (15.4) 36 (27.1) 24 (40.7)
Pathological T stage, n (%)
pT2 572 (78.1) 453 (83.9) 91 (68.4) 28 (47.5) <0.001
pT3a 77 (10.5) 43 (8) 20 (15) 14 (23.7)
pT3b 83 (11.4) 44 (8.1) 22 (16.5) 17 (28.8)
Pathological N stage, n (%)
pNx 390 (53.3) 302 (55.9) 57 (42.9) 31 (52.5) 0.003
pN0 293 (40) 212 (39.3) 61 (45.9) 20 (33.9)
pN1 49 (6.7) 26 (4.8) 15 (11.3) 8 (16.3)
Perioperative factors
OT, min, median (IQR) 200 (160–240) 195 (160–230) 210 (165–245) 210 (155–250) 0.054
Blood loss, mL, median (IQR) 300 (200–500) 300 (200–500) 300 (200–450) 300 (200–500) 0.554
ePLND, n (%)
No 390 (53.3) 302 (55.9) 57 (42.9) 31 (52.3) 0.026
Yes 342 (46.7) 238 (44.1) 76 (57.1) 28 (47.5)
Nodes, n, median (IQR) 26 (21–33) 27 (21–34) 26 (22–32.7) (19.2–28.5) 0.348
NSRP, n (%)
No 87 (11.9) 63 (11.7) 21 (15.8) 3 (5.1) 0.163
Yes 600 (82) 440 (81.5) 106 (79.7) 54 (91.5)
Unknown 45 (6.1) 37 (6.9) 6 (4.5) 2 (3.4)
Surgeon volume, n (%)
Low 248 (33.9) 168 (31.1) 57 (42.9) 23 (39) 0.026
High 484 (66.1) 372 (68.9) 76 (57.1) 36 (61)
ASA score, n (%)
1–2 675 (92.2) 495 (91.7) 124 (93.2) 56 (94.9) 0.601
3–4 57 (7.8) 45 (8.3) 9 (6.8) 3 (5.1)
LOS, days, median (IQR) 4 (4–6) 4 (4–6) 4 (4–5) 5 (4–6) 0.069
Clavien–Dindo score, n (%)
0 557 (76.1) 417 (77.2) 97 (72.9) 43 (72.9) 0.628
1–2 154 (21) 110 (20.4) 31 (23.3) 13 (22)
>2 21 (2.9) 13 (2.4) 5 (3.8) 3 (5.1)
Re-admission, n (%)
No 711 (97.1) 522 (96.7) 132 (99.2) 57 (96.6) 0.271
Yes 21 (2.9) 18 (3.3) 1 (0.8) 2 (3.4)
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The risk of non-focal PSM was predicted only by
BPC (OR 1.018; P = 0.005) in the clinical model; by
extracapsular extension (OR 4.089; P < 0.001) and
seminal vesicle invasion (OR 4.074; P = 0.001) in the
pathological model; and by no factor in the periopera-
tive model (Table 2). In the overall model, BPC (OR
1.013; P = 0.044), extracapsular extension (OR 4.832;
P < 0.001) and seminal vesicle invasion (OR 5.153;
P = 0.001) were associated with the risk of non-focal
PSMs (Table 3).
Considering diﬀerences between PSM subgroups,
BMI and high surgeon volume were the only
predictors that were associated with the risk of focal
PSM. Considering, similarities between PSM sub-
groups, BPC, pT3a and pT3b were factors that were
associated with the risk of both focal and non-focal
PSMs.
In Table 4, we stratiﬁed the SM status by tumour
pathological stage and compared them between low-
and high-volume surgeons. The high-volume surgeon
had better oncological results when compared to low-
volume surgeons (15.7% vs 23%). When stratiﬁed by
tumour stage, the diﬀerence was substantial for pT2
(13.6% vs 20.5%) and pT3a stage (19.1% vs 36.7%).
Table 2. Multivariate models of factors associated with the risk of PSM in the 732 patients who underwent RARP.
Focal vs negative SMs Non focal vs negative SMs
Variable OR (95%CI) P OR (95%CI) P
Clinical model
BMI 0.919 (0.863–0.980) 0.009 0.981 (0.889–1.071) 0.369
PSA 1.012 (0.980–1.045) 0.464 1.018 (0.984–1.053) 0.304
BPC 1.013 (1.004–1.023) 0.005 1.018 (1.005–1.031) 0.005
Biopsy grade group 1 Ref. Ref
Biopsy grade group 2–3 1.216 (0.805–1.835) 0.353 0.753 (0.406–1.398) 0.369
Biopsy grade group 4–5 0.994 (0.488–2.024) 0.994 1.617 (0.726–3.603) 0.240
Pathological model
Pathological grade group
1 Ref. Ref.
2–3 1.527 (0.841–2.773) 0.164 1.864 (0.634–5.475) 0.258
4–5 1.952 (0.921–4.139) 0.081 3.128 (0.935–10.454) 0.064
Pathological T stage
pT2 Ref. Ref.
pT3a 1.972 (1.081–3.599) 0.027 4.089 (1.924–8.690) <0.001
pT3b 1.773 (0.932–3.375) 0.081 4.074 (1.845–8.998) 0.001
Pathological N stage
pN0–x Ref. Ref.
pN1 1.574 (0.745–3.325) 0.235 1.156 (0.448–2.981) 0.764
Perioperative model
ePLND
No Ref. Ref.
Yes 1.675 (1.140–2.461) 0.009 1.138 (0.664–1.952) 0.638
Surgeon volume
Low Ref. Ref.
High 0.609 (0.412–0.900) 0.013 0.709 (0.407–1.134) 0.224
Figure 2. Anatomical sites of PSMs by linear extent (focal/non-focal) in 192 cases.
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Discussion
PSM rates after RARP in contemporary series range
from 15% to 29.5% [31–37]; with the PSM rate in our
present study (26.2%) consistent with these series. We
showed that PSM can be evaluated according to the
linear extent of cancer in a simple and eﬀective way,
with focal PSMs detected more frequently (18.2%)
than non-focal patterns (8.1%). The extent of cancer
involving the SM is a feature that should be consid-
ered when counselling patients after RP.
PSM after RP represents an unfavourable outcome,
which increases the risk of biochemical recurrence
(BCR). The length of the PSM is also an increasingly
negative prognostic factor [3–10]. Although measure-
ment of the whole linear extent of a PSM is suggested
[7], it is not routinely applied in clinical practice
because it is time consuming [3–10]. Patients with non-
focal PSMs are expected to have higher rates of BCR
than those with focal patterns, and the risk of biochem-
ical persistence is higher for the former [38–40].
Patients with non-focal PSMs are at increased risk of
a second treatment after RARP and this is a critical
issue that should be extensively explained when coun-
selling patients [38–40]. Diﬀerent thresholds have been
used in the literature to describe focal PSM. Particularly,
Servoll et al. [38] have shown that a PSM length >3 mm
was an independent predictor of cancer recurrence in
303 patients who underwent open RP. Sammon et al.
[39] used 1 mm as a threshold in 794 patients under-
going perineal RP and they found that at a median
follow-up of 54 months, the 5-year BCR-free probability
was 90.8% in patients with negative SMs, 77.5% in
patients with focal (<1 mm) PSMs, and 47.5% in
patients with broad (>1 mm) PSMs. Lee et al. [40]
demonstrated that focal (<3 mm) PSMs after RP does
not signiﬁcantly aﬀect BCR-free survival in 1733
patients with prostate cancer. Because RARP was per-
formed in our present cohort, we have chosen 1 mm as
our threshold and evaluated the linear extent of PSM in
two groups that were simple to compute and allowed
a division of the population of patients into two
subsets.
It is important to identify predictive factors of PSMs
in clinical practice, in order to deﬁne the risk, to plan
the surgery, and to anticipate the potential need for
adjuvant treatments after surgery. Therefore, patents
who are at risk of PSM need appropriate counselling
before and after RP due to the risk of needing adju-
vant or salvage treatments [3]. Detecting a PSM after
RP is an unfavourable outcome, which is dependent
on both surgery and tumour biology [3,4,6–10,13].
The former is related to technique and surgeon’s
experience, whilst the latter is dependent on tumour
stage, Gleason grade, and prostatic microenviron-
ment. In this context, in our previous experience, we
found that higher preoperative serum testosterone
levels were predictive of PSMs after RP [41]. The risk
of PSMs after RARP has been associated with various
clinical and pathological factors [31–33]. Clinical
Table 4. SM status stratiﬁed by tumour stage in low- and
high-volume surgeons.
Variable,
n (%) Subpopulation (*)
SM status (**)
Negative Focal PSM Non-focal PSM
Low-volume surgeons
Pathological tumour stage
pT2 190 (76.6) 141 (74.2) 39 (20.5) 10 (5.3)
pT3a 30 (12.1) 12 (40) 11 (36.7) 7 (23.3)
pT3b 28 (11.3) 15 (53.6) 7 (25) 6 (21.4)
Total 248 168 (67.7) 57 (23) 23 (9.3)
High-volume surgeon
Pathological tumour stage
pT2 382 (78.9) 312 (81.7) 52 (13.6) 18 (4.7)
pT3a 47 (9.7) 31 (66) 9 (19.1) 7 (14.9)
pT3b 55 (11.4) 29 (52.7) 15 (27.3) 11 (20)
Total 484 372 (76.9) 76 (15.7) 36 (7.4)
Legend: percentages are relative to columns (*) or rows (**).
Table 3. Combined multivariate models of factors associated with the risk of PSM in the 732 patients who underwent RARP.
Focal PSM vs negative SMs Non-focal PSM vs negative SMs
Variable OR (95%CI) P OR (95%CI) P
Clinical/perioperative model
BMI 0.915 (0.859–0.975) 0.006
BPC 1.012 (1.002–1.022) 0.014 1.021 (1.009–1.033) <0.001
ePLND
No Ref.
Yes 1.338 (0.878–2.039) 0.176
Surgeon volume
Low Ref.
High 0.577 (0.388–0.859) 0.007
Final overall model*
BMI 0.914 (0.857–0.974) 0.006
BPC 1.011 (1.002–1.021) 0.015 1.013 (1.000–1.023) 0.044
Pathological T stage
pT2 Ref. Ref.
pT3a 2.064 (1.145–3.722) 0.016 4.832 (2.348–9.943) <0.001
pT3b 2.15 (1.196–3.864) 0.010 5.153 (2.541–10.450) 0.001
Surgeon volume
Low Ref
High 0.574 (0.385–0.855) 0.006
*adjusted ORs.
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predictors include: BMI, PSA level, prostate volume,
BPC, biopsy grade group, and extraprostatic disease.
Pathological factors are characterised by cancer
extending beyond the prostate (pT3a and pT3b
stage), PSA level, prostate volume, BPC, biopsy grade
group, cT and pT stage, are factors that relate to
tumour extension, which increases the risk of PSMs
during prostate dissection. Further, in our previous
experience, we found that higher preoperative
serum testosterone levels were predictive of PSMs
after RP [41]. The association of BMI with the overall
risk of PSMs is a controversial topic, where published
data have found both that there is no association and
a positive association [33,42,43]. Patel et al. [33] sug-
gest that a positive association between BMI and
PSMs could be related to both reduced vision and
angle movements during RARP in obese patients.
A further step is to identify predictors of the linear
extent of PSM and also factors predicting BCR [10,26].
This issue is lacking in the literature.
Our present study showed that other factors were
able to diﬀerentiate the linear extent of PSM beyond
BPC and pT stage (Table 2; overall multivariate
model).
High BMI and high surgeon volume were both
independent factors that were associated with
a reduced risk of focal PSMs. The inﬂuence of BMI
during RARP is unclear. We previously found that
BMI is associated with major postoperative complica-
tions after RARP [44]. In the present study, we found
that BMI was independently associated with
a reduced risk of focal but not non-focal PSMs, and
this represents a new ﬁnding. This association may be
related to periprostatic fat tissue thickness, which is
more substantial in obese patients and thus they are
less likely to have focal PSM during RARP. Although
this hypothesis needs to be veriﬁed, it is supported by
a study showing a signiﬁcant correlation between BMI
and periprostatic fat thickness (r = 0.37), which was
measured by CT [40]. In the present study, we com-
pared RARP performed by ﬁve experienced surgeons.
One surgeon had performed >500 RARPs, whilst the
other four low-volume surgeons had performed
between 50 and 60 procedures. In the literature
there is no consensus about the number of the pro-
cedures a surgeon needs to complete in order to
reduce the PSM rate. Atug et al. [45] demonstrated
in the 2006 that experience gained over time led to
a decrease in the incidence of PSM. In that study
a reduction in PSM was found after ~30 procedures,
but the PSMs were not stratiﬁed according to their
extension. In our experience all surgeons overtook
this number of procedures when the evaluation of
patients started and we found only a correlation
with focal PSMs (≤1 mm). In this context, the experi-
ence of the surgical team should be discussed with
the patients during preoperative counselling.
A systematic review of the literature investigated
the subject of surgeon volume and oncological out-
comes [46]. The review found that overall oncologi-
cal outcomes are improved by increasing surgeon
volume. Hu et al. [47] reported that patients who
underwent RARP by high-volume surgeons were less
likely to undergo salvage therapy after RARP.
Moreover, Steinsvik et al. [48] found that the overall
risk of PSM after RARP was reduced in patients
undergoing RP by high-volume surgeons. Our pre-
sent study showed that high surgeon volume speci-
ﬁcally and independently decreased the risk of focal
PSM, which is a new ﬁnding. We stratiﬁed the SM
status by pathological tumour stage and compared
low- and high-volume surgeons (Table 4). For the
issue of focal PSM between surgeons, we found
that the high-volume surgeon had better oncologi-
cal results than the low-volume surgeons (15.7% vs
23%). When stratifying by tumour stage, the diﬀer-
ence was substantial for pT2 (13.6% vs 20.5%) and
pT3a stage (19.1% vs 36.7%). Our present results
show that surgeon volume is an independent factor
that reduces the risk of focal PSM in high-volume
centres; this is helpful during the learning curve
because it alerts low-volume surgeons to focus
more on the quality of the their surgery, as well as
stimulating high-volume surgeons to improve the
quality of their surgery to decrease the rate of focal
PSM in pT2 and pT3a disease. Additionally, con-
cerned patients, especially those with more aggres-
sive disease may seek high-volume surgeons in high-
volume centres in order to avoid the consequences
of a suboptimal RARP. Also, our present results may
further contribute to the notion that RARP should be
limited to high-volume surgeons at high-volume
centres. Referring physicians should consider this
when counselling patients before RARP.
Our present study has some limitations. First, the
retrospective nature of the present study is
a limitation in itself. Second, prostate volumes
and biopsies performed elsewhere were not re-
evaluated; however, their features had good stan-
dard quality to support their analysis. Third, in
some cases the pathologists did not report the
location, but just evaluated the linear extension of
the PSM. Fourth, we did not provide a threshold for
deﬁning high- and low-volume surgeons due to the
presence of a large diﬀerence between the single
high- and four low-volume surgeons and the
homogenous experience of the low-volume sur-
geons. For these reasons, we compared the cohort
of the patients who were operated on by the single
high-volume surgeon with the cohort of the
patients who were operated on by the other four
low-volume surgeons. However, beyond these lim-
its, our present study has much strength as it
includes a large contemporary cohort of patients
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and our dedicated pathologists assessed all
specimens.
Conclusions
In high-volume centres features related to host,
tumour and surgeon volume are important factors
that are associated with the risk of focal and non-
focal PSMs after RARP. Particularly, high-volume
surgeons have lower focal PSMs than low-volume
surgeons. These issues should be discussed when
counselling patients.
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